Omeros Corporation

OMERNASDAQ • USD
16.68 USD
↘ 0.81 (4.63%)AT CLOSE (03:59 PM EST)
14.99
↘ 1.69 (10.11%)
POST MARKET (AS OF 05:10 PM EST)
Post Market
AS OF 05:10 PM EST
14.99
↘ 1.69 (10.11%)
🟢Market: OPEN

OMER is currently priced at $14.99. Technical and fundamental signals converge bearish — technicals rate "Sell" while fundamentals read "Sell". Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. Valuation metrics place OMER at a fair price relative to peers.

Technical & fundamental data as of Nov 16, 2026.

Open?$17.39
High?$17.48
Low?$16.64
Prev. Close?$17.49
Volume?1.5M
Avg. Volume?1.1M
VWAP?$17.08
Rel. Volume?1.41x
Bid / Ask
Bid?$13.76 × 100
Ask?$21.44 × 100
Spread?$7.68
Midpoint?$17.60
Valuation & Ratios
Market Cap?1.3B
Shares Out?72.4M
Float?64.2M
Float %?88.7%
P/E Ratio?10.14
P/B Ratio?-24.66
EPS?$1.72
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
Employees
175
Market Cap
1.3B
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2009-10-08
Address
201 ELLIOTT AVENUE WEST
SEATTLE, WA 98119
Phone: 206-676-5000
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-1/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
33
Short Sent.?
20
Piotroski F-Score?0/9Weak
Altman Z-Score?-2.20Distress
Confidence?66%Moderate
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?19.99%High
Short Interest?12.8M
Days to Cover?9.6
Free Float64.2M
Avg Daily Volume1.3M
Settlement Date2026-10-30
Financial Health
Current Ratio?1.95Adequate
Quick Ratio?1.94Adequate
Cash Ratio?0.02Low
Debt/Equity?-1.43Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
73/100
P/E?
Peers
100
S&P
97
10.1CHEAP▾
P/B?
S&P
97
-24.66CHEAP▾
P/S?
Peers
100
S&P
3
32.95HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-18.6CHEAP▾
EV/Sales?
Peers
100
S&P
3
34.81HIGH▾
Returns & Efficiency
ROE?
S&P
3
-243.1%WEAK▾
ROA?
Peers
50
S&P
97
43.5%STRONG▾
Cash Flow & Enterprise
FCF?$-68728000
Enterprise Value?$1.3B
Fundamentals ratios updated end of day